gastroplus software 9.8 version  (Simulations Plus Inc)

Journal: Molecular Pharmaceutics

Article Title: Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An In Vivo – In Vitro – In Silico Approach

doi: 10.1021/acs.molpharmaceut.3c00016

Figure Lengend Snippet: PBPK plasma predictions. Observed and simulated encorafenib exposures as a function of time following administration of a single 100 mg dose of encorafenib in fasted, fed, and fasted with coadministration conditions. Simulations are depicted by the solid lines, whereas the mean encorafenib concentration observed at each time point are depicted as dots. n = number of participants used to calculate the mean encorafenib concentration at each time point.

Article Snippet: Simulations were performed using the commercially available PBPK modeling platform GastroPlus 9.8 (Simulations Plus, Inc., Lancaster, CA).

Techniques: Clinical Proteomics, Concentration Assay

Journal: Molecular Pharmaceutics

Article Title: Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An In Vivo – In Vitro – In Silico Approach

doi: 10.1021/acs.molpharmaceut.3c00016

Figure Lengend Snippet: PBPK Model Parameters

Article Snippet: Simulations were performed using the commercially available PBPK modeling platform GastroPlus 9.8 (Simulations Plus, Inc., Lancaster, CA).

Techniques: Diffusion-based Assay, Solubility, In Vitro, Permeability, In Vivo

Journal: Cancers

Article Title: Pharmacokinetic Basis for Using Saliva Matrine Concentrations as a Clinical Compliance Monitoring in Antitumor B Chemoprevention Trials in Humans

doi: 10.3390/cancers15010089

Figure Lengend Snippet: Model structure of the PBPK model of matrine using GastroPlus ® 9.8.

Article Snippet: The PBPK model of Matr in blood/plasma was developed using GastroPlus ® 9.8 software (Simulations Plus, Inc., Lancaster, CA, USA).

Techniques: